BIOGENERA SpA

𝗕𝗶𝗼𝗴𝗲𝗻𝗲𝗿𝗮’𝘀 𝗕𝗚𝗔𝟬𝟬𝟮 𝗳𝗲𝗮𝘁𝘂𝗿𝗲𝗱 𝗯𝘆 EPTRI EPTRI (European Paediatric Translational Research Infrastructure) has highlighted our multi-center Phase 1 clinical trial of BGA002, the first-in-class therapy targeting MYCN oncogene in aggressive pediatric cancers. 🔗 Read the full article here: https://lnkd.in/dxTTUGF3 #Biogenera #BGA002 #PrecisionMedicine #PediatricCancer #ClinicalTrials #OncologyInnovation #GeneTherapy #MYCN

BIOGENERA SpA has arrived at BIO-Europe Spring 2025! We’re here in Milan for one of the most important biotech and pharma partnering events of the year! Our team is ready to connect with industry leaders, investors, and innovators to discuss the future of precision medicine and targeted therapies. 📍 If you’re at BIO-Europe Spring, let’s meet! Reach out to schedule a conversation and learn more about how Biogenera is shaping the future of cancer treatment. #Biogenera #BioEuropeSpring #Biotech #PrecisionMedicine #Oncology #CancerResearch #Partnering #Innovation

𝟭 𝗪𝗲𝗲𝗸 𝘁𝗼 𝗚𝗼! Biogenera @ Bio-Europe Spring 2025 in Milan The countdown is on! In just one week, Biogenera will be at Bio-Europe Spring 2025, one of the most important partnering events in the biotech and pharma industries. From March 17 to 19, our team will be in Milan, ready to connect with industry leaders, investors, and partners. 💡 Why Meet Us? 🔬 We are pioneering MyGenera™ technology, a revolutionary platform that silences disease-causing genes at the DNA level. 💊 BGA002, our breakthrough therapy targeting the MYCN oncogene, is moving toward Phase 1 clinical trials and has obtained Orphan Drug Designations from the FDA & EMA. 🤝 We are actively seeking strategic partnerships and collaborations to accelerate innovation in precision medicine. 📅 Don't miss the chance to meet us in Milan! Book a meeting via PartneringONE or contact us directly to explore collaboration opportunities. We look forward to engaging with fellow innovators and driving forward the future of cancer treatment! . #Biogenera #BioEuropeSpring #Innovation #Biotech #PrecisionMedicine #Partnerships #CancerTreatment #BGA002 #MyGenera #LifeSciences

🎗️ Today is Rare Disease Day – A Call for Innovation and Hope 🎗️ At Biogenera, we are committed to improving the lives of patients with rare and life-threatening diseases, for whom treatment options are often limited or nonexistent. Our mission: Transforming precision medicine for rare cancers Rare diseases affect millions worldwide, yet research and innovation in this field remain challenging. Through our MyGenera™ platform, we are pioneering a new class of targeted biopharmaceuticals, with a focus on MYCN-driven cancers, including: - Neuroblastoma (one of the most aggressive pediatric tumors) - Rhabdomyosarcoma & Wilms' tumor - Small Cell Lung Cancer and other MYCN-expressing malignancies Let’s raise awareness and advocate for more breakthroughs in rare disease research: #Together, we can make a difference. . . #RareDiseaseDay #Biogenera #PrecisionMedicine #BGA002 #MYCN #RareCancers #OrphanDrugs #Innovation #HopeForPatients

🔬 Biogenera: Pioneering Research to Silence the MYCN Oncogene 🔬   At BIOGENERA SpA, our mission is to transform cancer treatment by targeting one of the most aggressive drivers of tumor progression: MYCN.  🧬 What is MYCN?   - MYCN is a gene that plays a crucial role during embryonic development but is silenced in normal tissues after birth.   - However, in many aggressive pediatric and adult cancers, MYCN becomes deregulated, driving uncontrolled cell proliferation, metastasis, and resistance to treatment.  Why is MYCN a key target in oncology? - MYCN is a marker of poor prognosis: high MYCN expression is associated with rapid tumor progression and lower survival rates.   - It contributes to immune escape, drug resistance, metastasis, and cancer stem cell survival, making tumors harder to treat.   - MYCN-driven cancers include aggressive neuroblastoma, rhabdomyosarcoma, Wilms’ tumor, medulloblatoma, acute leukemias in children and aggressive adult cancers like small cell lung cancer and glioblastoma. Biogenera’s Breakthrough: MyGenera™ & BGA002   Using our proprietary MyGenera™ technology, we have developed BGA002, the first-ever drug designed to selectively silence MYCN at the DNA level. This pioneering anti-gene therapy directly inhibits tumor growth while sparing healthy cells, paving the way for a new class of highly targeted cancer treatments.  The Future of Cancer Therapy Starts Here   Biogenera is advancing BGA002 into Phase 1 clinical trials, marking a critical step in delivering next-generation precision medicine to patients. We are committed to revolutionizing oncology with innovative DNA-based therapies* that offer new hope for those battling MYCN-driven cancers.  📢 Stay connected to follow our progress and learn more about how we are shaping the future of personalized medicine!   . . #Biogenera #CancerResearch #PrecisionMedicine #MYCN #Oncology #BGA002 #Biotech #Innovation #LifeSciences

BIOGENERA SpA at Tech in Healthcare 2025 – Innovation in Precision Medicine - SDA Bocconi🔬 Yesterday, Roberto Tonelli (Founder of Biogenera and Professor of Pharmacology at the University of Bologna) and Massimiliano Cesarini (CEO of Biogenera), took the stage at Tech in Healthcare 2025 at SDA Bocconi, presenting on: 📢 “A New Class of Biopharmaceuticals for Precision Medicine: DNA Cures” Biogenera is at the forefront of biotech innovation, leveraging cutting-edge DNA-based therapies to revolutionize precision medicine. Our MyGenera™ platform is paving the way for highly targeted treatments, including our lead drug candidate BGA002, designed to tackle MYCN-expressing tumors in pediatric and adult cancers. 💡 The event brought together top industry leaders to discuss the impact of artificial intelligence, analytics, medical devices, and biotechnology in healthcare. Roberto’s talk highlighted how Biogenera’s approach is redefining the future of oncology, offering a new paradigm in drug development. 🚀 We are proud to be part of this transformation in healthcare, and we look forward to continuing our mission to bring innovative, life-changing therapies to patients worldwide. 📍 Tech in Healthcare 2025 | SDA Bocconi | Milan . #Biogenera #PrecisionMedicine #DNAcures #Biotechnology #CancerResearch #TechInHealthcare #Innovation #BGA002 🚀

🎤 𝗝𝗼𝗶𝗻 𝗕𝗶𝗼𝗴𝗲𝗻𝗲𝗿𝗮 𝗮𝘁 𝘁𝗵𝗲 𝗜𝗦𝗣𝗘 𝗪𝗲𝗯𝗶𝗻𝗮𝗿!   We are excited to announce that our CEO, Massimiliano Cesarini, will be a featured speaker at the upcoming ISPE Webinar on Thursday, February 13, where industry experts will discuss key challenges and solutions in accelerating the launch of new drug products.  💡 𝗕𝗿𝗶𝗻𝗴𝗶𝗻𝗴 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝘁𝗼 𝗺𝗮𝗿𝗸𝗲𝘁 𝗶𝘀 𝗻𝗼 𝗲𝗮𝘀𝘆 𝘁𝗮𝘀𝗸 From navigating regulatory hurdles to optimizing aseptic processes, every step requires strategic execution. This webinar will provide actionable insights to:   ✅ Identify key limiting factors in speed to market   ✅ Overcome regulatory and manufacturing challenges   ✅ Optimize aseptic drug development for faster commercialization  🔬 At Biogenera, we are committed to revolutionizing oncology treatments with our MyGenera™ platform and leading drug candidate BGA002, targeting MYCN-expressing cancers. Our expertise in precision medicine and biotech innovation will contribute to this high-level discussion.  📢 Don’t miss this opportunity to gain insights from top industry leaders!   📅 Thursday, February 13 | 10:00-11:30 EST  🔗 𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗻𝗼𝘄: https://lnkd.in/gMj5K8CA . #Biogenera #ISPEWebinar #Innovation #DrugDevelopment #Biotech #AsepticProcessing #BGA002 #CancerTherapy

🔬 𝗕𝗚𝗔𝟬𝟬𝟮: 𝗧𝗵𝗲 𝗙𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗖𝗮𝗻𝗰𝗲𝗿 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 At BIOGENERA SpA, we are pioneering a new frontier in precision medicine. BGA002 (our most advanced new drug in the pipeline) specifically targets the MYCN cancer gene to cure MYCN-expressing tumors (50% of pediatric and 25% of adult cancers respectively, commonly sharing highly aggressive behaviors). This innovative therapy, based on our proprietary MyGenera™️ anti-gene platform, is designed to cure the disease at its source by specifically inhibiting the expression of the causative gene at the DNA level.   💡 𝗪𝗵𝘆 𝗕𝗚𝗔𝟬𝟬𝟮 𝗶𝘀 𝗮 𝗯𝗿𝗲𝗮𝗸𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝗶𝗻 𝗰𝗮𝗻𝗰𝗲𝗿 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁: Targeted action: Specifically developed block the expression of MYCN gene, for the cure of MYCN-expressing tumors. MYCN is expressed in cancer cells but is not expressed in normal cells, thus BGA002 selectively kills cancer cells. Orphan drug designation: This status, obtained by the EMA and FDA regulatory agencies, provides accelerated access to the market and enhanced return on investment. Positive preclinical results: BGA002 successfully completed preclinical studies, demonstrating potent anti-tumor activity and well-tolerated safety profile, paving the way for the upcoming Phase 1 clinical trial, set to begin in the second half of 2025 in MYCN-expressing children tumors. 🔬 𝗔𝗯𝗼𝘂𝘁 𝘁𝗵𝗲 𝗠𝘆𝗚𝗲𝗻𝗲𝗿𝗮™️ 𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺 Our proprietary MyGenera™️ biotechnology enables the rapid development of new anti-gene oligonucleotide (oligo) therapies. Unlike traditional "anti-sense" oligo targeting RNA, our method acts directly on the DNA to prevent disease progression, enabling lower doses and fewer administrations.   🌍 𝗔𝗱𝗱𝗿𝗲𝘀𝘀𝗶𝗻𝗴 𝗵𝗶𝗴𝗵 𝘂𝗻𝗺𝗲𝘁 𝗺𝗲𝗱𝗶𝗰𝗮𝗹 𝗻𝗲𝗲𝗱𝘀 Approximately 50% of all pediatric tumors express the MYCN oncogene; this technology also holds potential for adult malignancies (25% of the total), such as small cell lung cancer (an orphan drug already obtained by the FDA). With a global market potential of over €1.3 billion for Neuroblastoma (an orphan drug obtained by the EMA and FDA and a first-to-market indication), BGA002 represents a life-saving opportunity for patients and a high-impact investment.   📈 𝗢𝘂𝗿 𝗩𝗶𝘀𝗶𝗼𝗻 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗙𝘂𝘁𝘂𝗿𝗲 As we advance towards the Euronext Paris StockExchange listing, Biogenera remains committed to innovation, expanding our international reach, and transforming cancer treatment and other severe diseases with unmet medical needs through its precision medicine science.   👉 Stay connected with us to learn more about our journey and upcoming milestones. Together, we can create a brighter future for cancer care.  . #Biogenera #Innovation #CancerTreatment #BGA002 #PrecisionMedicine #Biotech #ClinicalTrials #MYCN #EuronextParis #LifeSciences

𝗕𝗶𝗼𝗴𝗲𝗻𝗲𝗿𝗮 @ 𝗕𝗶𝗼-𝗘𝘂𝗿𝗼𝗽𝗲 𝗦𝗽𝗿𝗶𝗻𝗴 𝟮𝟬𝟮𝟱 𝗶𝗻 𝗠𝗶𝗹𝗮𝗻! We are excited to announce our participation in Bio-Europe Spring 2025, one of the most important events in the biotech and pharma industries, in Milan from March 17 to 19, 2025. 📢 Our Head of Business Development, Federico Ragni, and the Biogenera team will connect with industry leaders, partners, and investors to showcase our cutting-edge innovations in cancer treatment and precision medicine. 💡 𝗪𝗵𝗮𝘁 𝗺𝗮𝗸𝗲𝘀 𝗕𝗶𝗼𝗴𝗲𝗻𝗲𝗿𝗮 𝘂𝗻𝗶𝗾𝘂𝗲? Our proprietary MyGenera™ technology: A groundbreaking platform that rapidly develops therapies by silencing disease-causing genes at the DNA level. 𝗕𝗚𝗔𝟬𝟬𝟮: The first-ever drug targeting the MYCN oncogene, a key driver of aggressive pediatric and adult cancers. BGA002 has obtained Orphan Drug Designations from the FDA and EMA and is preparing for Phase 1 clinical trials. A vision to expand our pipeline into high-need therapeutic areas, transforming the future of personalized medicine. 🤝 We look forward to meeting potential partners and exploring collaboration opportunities. Contact us via partneringONE to book a meeting or learn more about our BGA002 program and MyGenera™ platform. 📅 Save the date and meet us in Milan! #Biogenera #BioEuropeSpring #Innovation #Biotech #PrecisionMedicine #Partnerships #CancerTreatment #BGA002 #MyGenera #LifeSciences

ready to go!!!